107534-93-0
107534-93-0
Chemical Structure
Macelignan
Synonym(s): (+)-Anwulignan; Anwuligan
- CAS No.: 107534-93-0
- Formula:C20H24O4
- Molecular Weight:328.40
IUPAC Name: 4-((2S,3R)-4-(benzo[d][1,3]dioxol-5-yl)-2,3-dimethylbutyl)-2-methoxyphenol
InChIKey: QDDILOVMGWUNGD-UONOGXRCSA-N
SMILES: OC1=CC=C(C[C@H](C)[C@H](C)CC2=CC=C(OCO3)C3=C2)C=C1OC
Biological Activity: Macelignan ((+)-Anwulignan; Anwuligan)?is an orally active lignan isolated from Myristica fragrans. Macelignan possesses many pharmacological activities, including anti-inflammatory, anti-cancer, anti-diabetes, and neuroprotective activities[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Macelignan | 99.78% | Macelignan ((+)-Anwulignan; Anwuligan)?is an orally active lignan isolated from Myristica fragrans. Macelignan possesses many pharmacological activities, including anti-inflammatory, anti-cancer, anti-diabetes, and neuroprotective activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Macelignan (Standard) | ≥98% | Macelignan (Standard) is the analytical standard of Macelignan. This product is intended for research and analytical applications. Macelignan ((+)-Anwulignan; Anwuligan) is an orally active lignan isolated from Myristica fragrans. Macelignan possesses many pharmacological activities, including anti-inflammatory, anti-cancer, anti-diabetes, and neuroprotective activities. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Anggakusuma, et al. Effects of macelignan isolated from Myristica fragrans Houtt. on UVB-induced matrix metalloproteinase-9 and cyclooxygenase-2 in HaCaT cells. J Dermatol Sci [Content Brief]
- [2]. Jiyoung Yeo, et al. Effects of a multi-herbal extract on type 2 diabetes. Chin Med. 2011 Mar 4;6:10. [Content Brief]
- [3]. Chun-Ai Cui, et al. Macelignan attenuates LPS-induced inflammation and reduces LPS-induced spatial learning impairments in rats. Neurosci Lett. 2008 Dec 19;448(1):110-4. [Content Brief]
Keywords
